한빛사 논문
Abstract
Jongsook Kim Kemper1,*, Zhen Xiao2, 4, Bhaskar Ponugoti1, 4, Ji Miao1, 4, Sungsoon Fang1, Deepthi Kanamaluru1, Stephanie Tsang1, Shwu-Yuan Wu3, Cheng-Ming Chiang3 and Timothy D. Veenstra2
1 Department of Molecular and Integrative Physiology, University of Illinois, Urbana, IL 61801, USA
2 Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, Frederick, MD, USA
3 Simmons Comprehensive Cancer Center, Department of Biochemistry and Department of Pharmacology, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA
* Corresponding author
4 These authors contributed equally to this work
Summary
The nuclear bile acid receptor FXR is critical for regulation of lipid and glucose metabolism. Here, we report that FXR is a target of SIRT1, a deacetylase that mediates nutritional and hormonal modulation of hepatic metabolism. Lysine 217 of FXR is the major acetylation site targeted by p300 and SIRT1. Acetylation of FXR increases its stability but inhibits heterodimerization with RXRα, DNA binding, and transactivation activity. Downregulation of hepatic SIRT1 increased FXR acetylation with deleterious metabolic outcomes. Surprisingly, in mouse models of metabolic disease, FXR interaction with SIRT1 and p300 was dramatically altered, FXR acetylation levels were elevated, and overexpression of SIRT1 or resveratrol treatment reduced acetylated FXR levels. Our data demonstrate that FXR acetylation is normally dynamically regulated by p300 and SIRT1 but is constitutively elevated in metabolic disease states. Small molecules that inhibit FXR acetylation by targeting SIRT1 or p300 may be promising therapeutic agents for metabolic disorders.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기